Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QVMVT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
YH-012
|
|||||
| Synonyms |
YH012; YH 012
Click to Show/Hide
|
|||||
| Organization |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.; Eucure (Beijing) Biopharma Co., Ltd.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 5 Indication(s)
Bladder cancer [ICD11:2C94]
Clinical candidate
Breast cancer [ICD11:2C60-2C65]
Clinical candidate
Colorectal cancer [ICD11:2B91]
Clinical candidate
Gastric cancer [ICD11:2B72]
Clinical candidate
Non-small cell lung cancer [ICD11:2C25]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2); Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.